Solutions · Research labs

The assumption
your programme
depends on.

Every research programme is built on a stack of assumptions. Most hold. One won't. The question is whether you find it before you've committed three years and $4M of capital to a programme that fails on a premise you never stress-tested. Augle finds it — and tells you precisely what evidence would resolve it.

Principal investigators at Phase I–III decision points
Lab directors commissioning landmark finding audits
Research directors evaluating trial design choices
Drug discovery teams assessing target viability
Programme leads stress-testing foundational literature
Session configuration · Research labs
GuardianAcademic integrity
SVS checksRetraction DB · erratum tracking · preprint flag
DocumentsLiterature summaries · trial briefs · programme memos
DepthStandard or Deep
OutputCritical assumption identification · evidence-anchored finding · resolution pathway
The problem

High-stakes decisions
built on literature

you haven't audited.

Research programme decisions happen fast. Literature summaries are compiled by team members with domain expertise but limited adversarial instinct. Errata go uncited. Foundational papers accumulate credibility without replication. By the time a programme fails, the assumption that killed it was visible in the evidence base from the start.

Questions research labs run on Augle

Does the published evidence support this target's viability, or are we building on a single unreplicated finding?
Which trial design is better supported for this indication — adaptive platform or randomised controlled?
Does the landmark finding we're building this programme on have adequate replication and methodological integrity?
Are any of our foundational citations affected by errata, retractions, or effect size corrections?
What is the specific data gap that, if unresolved, makes this programme's core hypothesis fail?
The erratum that changed the evidence weight

The Guardian's SVS tracks published errata across cited papers. A 2017 meta-analysis treated as confirmatory with a 31% reduction in pooled effect size after erratum — uncited in the team's literature summary — can rewrite the evidence weight assessment for every node that depended on it.

Design decisions built on inapplicable precedents

The Contrarian checks whether cited precedents actually apply to your specific context. Adaptive platform trials that demonstrated efficiency gains in characterised biomarker landscapes don't automatically support the same design in an uncharacterised one — and the Contrarian will say so, specifically.

The assumption your programme can't survive without

The Methodologist traces which evidence nodes are load-bearing — which ones, if they fail, take the programme with them. The output names that assumption explicitly, specifies what data would resolve it, and estimates whether resolving it is feasible within your timeline and budget.

Literature reviewed by people who want the programme to succeed

Team members reviewing their own programme's foundational literature have a structural conflict of interest. The Contrarian has none. It is architecturally required to steelman every claim before challenging it — which means it produces the strongest possible case for your programme before finding the objection that case doesn't fully answer.

How it works in practice

Three sessions.
Three decision points.

Each scenario is drawn from the Augle Use Case Compendium — hypothetical sessions illustrating realistic deliberation behaviour across the research lab lifecycle.

Use case 01 of 03 · Research labs
The New Drug Target Assessment
Research Director, Oncology · Pre-programme go/no-go decision
Standard depth

Is the published evidence for this oncology target sufficient to justify committing to a three-year, $4M research programme, or are there foundational assumptions that require resolution first?

CartographerSettled: target is expressed in the relevant tumour type. Contested: whether expression level correlates with functional dependency — one study shows correlation, two show no significant relationship. Unknown: human orthologue binding data for the proposed inhibitor class.
MethodologistThe correlation study uses a mouse model with a known metabolic difference from the human orthologue. External validity concern: the correlation may not transfer. This is the load-bearing assumption.
ContrarianStrong objection: "This is where the programme fails if it fails. A single binding assay in the human orthologue resolves the highest-risk assumption at minimal cost before full commitment."
PragmatistTwo paths: (1) 6–8 week translation checkpoint with a targeted binding assay before full programme commitment. (2) Proceed with embedded checkpoint at 6-month milestone. Path 1 resolves the critical assumption cheaply.
Session output
FindingContested — critical assumption unresolved. Not a no-go, but not an unconditional go.
Key riskHuman orthologue binding — single cheap assay resolves it
Resolution6–8 week checkpoint before full capital commitment
SVSOne cited comparable is a conference abstract — cannot be treated as primary evidence
The value

The lab director didn't get a yes or no. She got the specific assumption the programme depends on and a decision structure that resolves it cheaply before full sunk cost accumulates.

Use case 02 of 03 · Research labs
The Clinical Trial Design Decision
Principal Investigator, Oncology · Phase II design review
Standard depth · document ingestion

For a combination immunotherapy Phase II trial in this indication, which trial design — randomised controlled or adaptive platform — is better supported by the available methodological and clinical evidence?

CartographerSettled: adaptive platform designs have demonstrated efficiency gains in heterogeneous tumour populations. Contested: whether gains hold in combination therapy with uncharacterised interaction effects. Unknown: specific biomarker landscape for this indication at population level.
MethodologistInternal validity concern: adaptive design interim decision rules require a 12-week biomarker signal. Published response kinetics for this drug class show high variability through week 16 — the interim may fire on noise. RCT does not have this dependency.
ContrarianStrong objection: "The three cited precedent trials all had pre-characterised biomarker landscapes from Phase I data. This trial does not. Adaptive design efficiency gains are contingent on biomarker reliability — in an uncharacterised landscape, adaptive design adds complexity without the efficiency benefit."
SynthesizerAdaptive design: Probable in principle, Contested for this specific trial. The Contrarian objection is specific to this trial's data requirements — not resolved by general adaptive design evidence.
Session output
FindingAdaptive: Probable in principle, Contested here. RCT: lower ceiling but no biomarker dependency.
Decision driverEfficiency advantage is conditional on reliable 12-week biomarker signal — currently absent
Paths(1) Biomarker study first (+4–6 months). (2) RCT with embedded biomarker substudy for Phase III.
The value

The PI was leaning toward the adaptive design based on general literature. The ensemble surfaced the specific data dependency that makes the adaptive design's efficiency advantage unavailable in this trial — a finding that changes the protocol decision without requiring new experiments.

Use case 03 of 03 · Research labs
The Landmark Finding Audit
Lab Director, Cognitive Neuroscience · Pre-programme literature review
Deep · full 3-round ensemble

Does the 2016 default mode network prospective memory finding have sufficient replication and methodological integrity to serve as a foundational assumption for a new multi-year research programme?

Guardian SVSCritical flag: a 2017 meta-analysis the team treats as confirmatory has a published erratum reducing the pooled effect size by 31%. The erratum is not cited in the team's summary. Corrected data changes evidence weight for two dependent nodes.
CartographerWith corrected meta-analysis: Settled: original activation pattern is replicable. Contested: whether the prospective memory specificity claim holds — the erratum shifts the evidence toward a more general attention effect.
ContrarianStrong objection: "The prospective memory specificity claim — the finding this programme depends on — rests on the uncorrected effect size. The corrected meta-analysis cannot support specificity at the level the original paper claimed."
SynthesizerGeneral DMN involvement in prospective memory: Probable. Specificity claim as foundational programme assumption: Contested. The programme can proceed on the general finding but not the specificity claim.
Session output
SVS flagUncited erratum — 31% effect size reduction in key meta-analysis
FindingGeneral DMN involvement: Probable. Specificity claim: Contested.
ProgrammeReframe around general DMN involvement. Specificity requires new data before becoming a programme assumption.
The value

The team's literature summary cited the 2017 meta-analysis as confirmatory without the erratum. Augle's SVS caught it. The corrected effect size changes what the programme can assume — catching this before programme launch avoids building three years of work on a specificity claim the corrected evidence doesn't support.

How Augle works for research labs

Adversarial review before
the capital is committed.

1
Upload your literature summary or programme brief

Submit the question alongside your team's literature summary, trial design brief, or programme memo. The Guardian immediately begins SVS authentication across every cited source — checking for retractions, errata, and preprint status before deliberation begins.

2
The Methodologist identifies load-bearing assumptions

Across all three deliberation phases, the Methodologist evaluates which evidence nodes are critical dependencies — the assumptions whose failure takes the programme with them. Each gets a confidence grade and an explicit statement of what would change it.

3
The Contrarian challenges applicability, not just existence

It's not enough that a precedent exists — it has to apply to your specific context. The Contrarian actively tests whether cited studies' populations, designs, and biomarker landscapes match your trial's requirements. Inapplicable precedents are called out specifically.

4
The output tells you what to do next, not just what's wrong

The Pragmatist translates the finding into a concrete decision structure — including the specific experiment, checkpoint, or data collection that would resolve the critical assumption at minimum cost and time before full programme commitment.

Research lab configuration · Guardian SVS
Erratum tracking
Published errata cross-referenced against cited papers — effect size corrections and scope limitations flagged and reflected in evidence node confidence grades
Retraction check
Every citation verified against Retraction Watch and publisher retraction databases before entering the evidence nodes registry — retracted papers blocked from deliberation
Conference abstracts
Non-peer-reviewed conference abstracts flagged SVS_UNVERIFIED — evidence node capped at Probable, cannot serve as primary evidence for load-bearing programme assumptions
Applicability check
Contrarian evaluates whether cited precedents' populations, designs, and conditions match your specific research context — not just whether they exist
Document ingestion
Literature summaries and programme briefs ingested as evidence — all citations within submitted documents authenticated via SVS before entering evidence nodes registry
Audit trail
Full session record including SVS verification log, erratum flags, objection register, and Pragmatist resolution pathway — exportable for programme documentation
Why Augle for research labs

What you can't get
from internal review.

SVS catches what literature review misses

Errata, retractions, and effect size corrections don't always propagate through the literature. The Guardian's Source Verification Service cross-references every cited paper against retraction databases and published errata — before the deliberation begins, not after you've built a programme on the finding.

It names the specific assumption, not general uncertainty

The Methodologist doesn't produce a risk register of things that could go wrong. It identifies the single load-bearing assumption — the one whose failure takes the programme with it — and provides the specific evidence that would resolve it. General uncertainty acknowledgments are not permitted outputs.

The Contrarian has no stake in your programme succeeding

Internal review is conducted by people who want the programme to succeed. The Contrarian is architecturally required to steelman every claim before challenging it — producing the strongest possible case for your hypothesis and then finding the objection that case doesn't fully answer. That's a structurally different process.

Precedent applicability, not just precedent existence

A cited precedent only supports your decision if it actually applies to your context. The Contrarian evaluates whether each precedent's population, design, biomarker landscape, and conditions match your specific research question. Citing an adaptive trial that succeeded in a characterised landscape doesn't support the same design in an uncharacterised one.

A decision structure, not just a finding

The Pragmatist produces a concrete resolution pathway — the specific checkpoint, assay, or substudy that resolves the critical assumption at minimum cost before full programme commitment. You don't just learn what's uncertain. You learn what to do about it, in what order, and at what cost.

$0.60 against a $4M commitment

A Standard deliberation costs $0.60. A three-year research programme costs millions. The economics of running an adversarial review before committing to a programme — or before locking a trial design — are straightforward. The question isn't whether you can afford to run Augle. It's whether you can afford not to.

Find the assumption
before it finds you.

Join the waitlist and get one Standard session free.
Run it on a programme decision that's live right now.